Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Sage Therapeutic stock
Learn how to easily invest in Sage Therapeutic stock.
Sage Therapeutic is a biotechnology business based in the US. Sage Therapeutic shares (SAGE) are listed on the NASDAQ and all prices are listed in US Dollars. Sage Therapeutic employs 471 staff and has a trailing 12-month revenue of around $6.5 million.
How to buy Sage Therapeutic stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – SAGE. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Sage Therapeutic stock price (NASDAQ: SAGE)Use our graph to track the performance of SAGE stocks over time.
Sage Therapeutic shares at a glance
|Latest market close||$44.51|
|52-week range||$27.36 - $49.56|
|50-day moving average||$39.67|
|200-day moving average||$37.18|
|Wall St. target price||$55.25|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-8.23|
Buy Sage Therapeutic stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Sage Therapeutic stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sage Therapeutic price performance over time
|1 week (2023-01-20)||4.57%|
|1 month (2022-12-27)||18.60%|
|3 months (2022-10-27)||19.27%|
|6 months (2022-07-27)||28.31%|
|1 year (2022-01-26)||17.91%|
|2 years (2021-01-27)||-44.73%|
|3 years (2020-01-27)||67.32|
|5 years (2018-01-26)||183.47|
Is Sage Therapeutic stock undervalued or overvalued?
Valuing Sage Therapeutic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sage Therapeutic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sage Therapeutic's PEG ratio
Sage Therapeutic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.74. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sage Therapeutic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Sage Therapeutic financials
|Revenue TTM||$6.5 million|
|Gross profit TTM||$-277,411,000|
|Return on assets TTM||-18.99%|
|Return on equity TTM||-31.74%|
|Market capitalisation||$2.7 billion|
TTM: trailing 12 months
Sage Therapeutic share dividends
We're not expecting Sage Therapeutic to pay a dividend over the next 12 months.
Sage Therapeutic share price volatility
Over the last 12 months, Sage Therapeutic's shares have ranged in value from as little as $27.36 up to $49.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sage Therapeutic's is 1.1353. This would suggest that Sage Therapeutic's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Sage Therapeutic overview
Sage Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co.
Sage Therapeutic in the news
Zacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB
Biotech's Blockbuster Week: 3 Stocks to Watch
Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength?
Frequently asked questionsWhat percentage of Sage Therapeutic is owned by insiders or institutions?
Currently 12.524% of Sage Therapeutic shares are held by insiders and 88.915% by institutions. How many people work for Sage Therapeutic?
Latest data suggests 471 work at Sage Therapeutic. When does the fiscal year end for Sage Therapeutic?
Sage Therapeutic's fiscal year ends in December. Where is Sage Therapeutic based?
Sage Therapeutic's address is: 215 First Street, Cambridge, MA, United States, 02142 What is Sage Therapeutic's ISIN number?
Sage Therapeutic's international securities identification number is: US78667J1088 What is Sage Therapeutic's CUSIP number?
Sage Therapeutic's Committee on Uniform Securities Identification Procedures number is: 78667J108
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert